• LAST PRICE
    0.7920
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.7920
  • Day Range
    ---
  • 52 Week Range
    Low 0.6720
    High 2.2200
  • Volume
    70

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeBICX
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBICX
BioCorRx Inc
6.7M
-1.6x
---
United StatesUSNU
US Neurosurgical Holdings Inc
4.3M
-36.9x
---
United StatesALBT
Avalon Globocare Corp
4.3M
-0.4x
---
United StatesMGRX
Mangoceuticals Inc
3.8M
-0.4x
---
United StatesGENE
Genetic Technologies Ltd
7.5M
-17.1x
---
United StatesPFHO
Pacific Health Care Organization Inc
8.7M
18.4x
+17.15%
As of 2024-02-22

Company Information

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. Its BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. It is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained-release, injectable naltrexone for the treatment of opioid abuse and alcoholism. It is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.

Contact Information

Headquarters
2390 East Orangewood Avenue, Suite 500ANAHEIM, CA, United States 92806
Phone
714-462-4880
Fax
---

Executives

President, Director
Louis Lucido
President, Chief Financial Officer, Treasurer, Director
Lourdes Felix
Executive Vice President
Thomas Welch
President, Director
Brady Granier
Independent Director
Kent Emry

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$6.7M
Revenue (TTM)
$153.1K
Shares Outstanding
8.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.53
EPS
$-0.49
Book Value
$-1.05
P/E Ratio
-1.6x
Price/Sales (TTM)
43.8
Price/Cash Flow (TTM)
---
Operating Margin
-2,733.49%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.